GlassScriptPhysician profile
Peter W Coppola
NPI 1134116148
$4,247.95
in general payments reported to CMS, 2019-2025
36 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $278 · 2021: $626 · 2022: $719 · 2023: $1,170 · 2024: $584 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948 · Education: $75.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.23 |
| Education | $75.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $604.64 | 2022-2023 | Xeomin |
| Glaxosmithkline, LLC. | $474.88 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $349.53 | 2019-2023 | Xarelto |
| Pfizer INC. | $310.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $310.32 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.55 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $200.70 | 2019-2025 | Ozempic, Rybelsus |
| Galderma Laboratories, L.P. | $191.50 | 2023-2025 | Dysport |
| Merck Sharp & Dohme LLC | $175.39 | 2019-2024 | Dificid |
| Allergan, INC. | $161.09 | 2019-2022 | |
| Abbvie INC. | $141.74 | 2021-2025 | |
| Exact Sciences Corporation | $106.99 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $105.39 | 2022-2024 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.34 | 2019-2024 | Trulance, Xifaxan |
| Novartis Pharmaceuticals Corporation | $93.65 | 2019-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $78.46 | 2020-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $68.81 | 2021 | |
| Medtronic, INC. | $59.69 | 2024 | Minimed 780g |
| Daiichi Sankyo INC. | $53.05 | 2019 | |
| Abbott Laboratories | $52.20 | 2021-2024 | Eterna, Freestyle Libre |
| Otsuka America Pharmaceutical, INC. | $34.87 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $29.69 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $28.64 | 2022 | |
| Hikma Pharmaceuticals USA | $28.62 | 2021-2022 | |
| Astellas Pharma US INC | $28.33 | 2019-2023 | Myrbetriq |
| Almatica Pharma LLC | $24.22 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $16.00 | 2023 | Gvoke Hypopen |
| Eisai INC. | $15.53 | 2024 | |
| Shield Therapeutics INC | $15.42 | 2022 | |
| Genentech USA, INC. | $14.99 | 2019 | |
| Medicure Pharma INC. | $14.81 | 2022 | |
| Amgen INC. | $14.73 | 2024 | Repatha |
| Philips North America LLC | $14.44 | 2024 | (Ck7) Extended Holter |
| Kowa Pharmaceuticals America, INC. | $14.22 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.64 | 2021 | |
| Circassia INC. | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Coppola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.